Home » Topics » BioWorld Science

BioWorld Science
RSS

Shanghai Pharmaceuticals Holding discloses IDO-1 inhibitors

May 14, 2018

Merck & Co. patents KDM5B inhibitors

May 14, 2018

Novel p95HER2-TCB demonstrates efficacy and safety in preclinical models of breast cancer

May 14, 2018

Porcine optic nerve injury model created to study nerve regeneration

May 14, 2018

RXi Pharmaceuticals enters research agreement with Iovance Biotherapeutics

May 14, 2018

First patient dosed in phase II study of eFT-508 plus avelumab in colorectal cancer

May 14, 2018

Mitsubishi Tanabe presents milestones of fourth quarter of fiscal 2017

May 14, 2018

New phase II proof-of-concept trial studies IXT-m200 in methamphetamine users

May 11, 2018

Lipimetix sublicenses Apo E mimetic peptide platform to Anji

May 11, 2018

Phase III GALATHEA trial of Fasenra in COPD does not meet primary endpoint

May 11, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...